News
About Vepdegestrant Vepdegestrant is an investigational, orally bioavailable PROteolysis TArgeting Chimera (PROTAC) estrogen receptor degrader. Vepdegestrant is being developed as a potential ...
The company reported a net loss attributable to common stockholders of $5.7 million, or $1.99 per share, for the three months ended June 30, 2025, compared to a net loss attributable to common ...
Focus on including foods high in calories, protein, and nutrients into your loved one’s diet when they are experiencing ...
With the field of HER2-positive breast cancer evolving rapidly, how will practice change in the clinic after the recent ...
NDA for icotrokinra for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque ...
General and administrative expenses were $1.9 million for the second quarter of 2025, as compared to $1.7 million for the second quarter of 2024. The increase was primarily driven by a $0.2 million ...
More and more providers are beginning to incorporate the new Practical Geriatric Assessment into their practices.
Two new studies show that colorectal cancer screening sharply increased for people ages 45 to 49 after the age recommendation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results